

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form 15-12B  
June 27, 2011

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION  
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934  
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 1-31773

Caraco Pharmaceutical Laboratories, Ltd.  
(Exact name of registrant as specified in its charter)

1150 Elijah McCoy Drive, Detroit, Michigan 48202 (313) 871-8400  
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, no par value  
(Title of each class of securities covered by this Form)

None  
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	S
Rule 12g-4(a)(2)	..
Rule 12h-3(b)(1)(i)	..
Rule 12h-3(b)(1)(ii)	..
Rule 15d-6	S

Approximate number of holders of record as of the certification or notice date: 2

Pursuant to the requirements of the Securities Exchange Act of 1934, Caraco Pharmaceutical Laboratories, Ltd. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

DATE: June 27, 2011

By: /s/ GP. Singh  
Name: GP. Singh  
Title: Chief Executive Officer

Instruction: This form is required by Rules 12g-4, 12h-3 and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

---

---